The securities of Tissue Therapies Limited (the “Company”) will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Monday, 25 February 2013 or when the announcement is released to the market.

Security Code: TIS

Nathan Bartrop
Senior Adviser, Listings Compliance
Application for trading halt - Tissue Therapies Limited (ASX Code: TIS)

The Company requests that the ASX Limited grant an immediate trading halt for TIS’ shares pending an announcement regarding a proposed capital raising.

In accordance with Listing Rule 17.1, TIS provides the following information:

(a) TIS requests that the trading halt continue until the earlier of the commencement of normal trading on Monday, 25 February 2013 or when TIS makes an announcement to the market and requests that the trading halt be lifted.

(b) TIS is not aware of any reason why the trading halt should not be granted.
What is VitroGro® ECM

- VitroGro® ECM is a topically applied, biomimetic scaffold, comprising a synthetic extracellular matrix (ECM) protein.
- How it works: VitroGro® ECM replaces the degraded matrix of a hard to heal wound. VitroGro® ECM binds to a prepared wound bed and provides a physical structure (a scaffold) for cell attachment, which is a primary requirement for subsequent cell functions critical for healing, such as cell proliferation and migration [1].
- An optimal scaffold: One of the characteristics of hard to heal wounds is prolonged inflammation, which damages the native ECM that would normally guide the wound healing process [1,2,3,4]. Replacement of this damaged ECM is a beneficial strategy for treating hard to heal wounds [1]. VitroGro® ECM is ideal as an ECM replacement since its structural and functional elements mimic those present in the ECM at the early stages of normal wound healing.
- Expert health economics modelling indicates that VitroGro® ECM offers the opportunity for substantially more cost effective treatment of wounds compared to the current standard of care.


About Tissue Therapies Limited

Tissue Therapies Limited is a biomedical technology company that is developing significantly more effective treatments for acute and chronic wound healing applications, including chronic skin ulcers and burns. Tissue Therapies Limited is commercialising VitroGro® ECM, a technology created by cell biology, tissue engineering and protein engineering experts at the Institute of Health and Biomedical Innovation at the Queensland University of Technology. The company is also developing treatments for psoriasis, scar prevention and various cancers including those of the breast, colon and prostate. Tissue Therapies Limited’s shares are traded on the Australian, Berlin and Frankfurt stock exchanges.

More information: www.tissuetherapies.com